On Sunday, the 15th of March 2020, Government sources in Berlin said that the Trump Administration had been on the lookout of a potential takeover of German firm, CureVac, which the sources claimed had made tremendous progress on developing coronavirus vaccines, while earlier on Sunday (March 15th) German local newspaper, Welt am Sonntag said in a report that the US President Donald Trump himself had offered a huge sum to Tübingen-based German Pharmaceutical, CureVac, that develops vaccines based on messenger RNA (an RNA that transmits information on which protein codon would be developed as the name suggests) and focuses on rare diseases, to lure it away in to the United States.
Besides, the German newspaper had also added in its Sunday’s (March 15th) report that the German Government made counter-offers to make it stay, while denying possibilities of any potential takeover, CureVac said in a statement later on Sunday (March 15th), “The company rejects current rumours of an acquisition.
” Meanwhile, confirming the feasibility of the Welt am Sonntag report that cited a US Government bid for the German vaccine developer CureVac, a German Health Ministry spokeswoman said late on Sunday (March 15th), “The German government is very interested in ensuring that vaccines and active substances against the new coronavirus are also developed in Germany and Europe.
In this regard, the government is in intensive exchange with the company CureVac. ” In point of fact, latest bidding war over potential coronavirus vaccine producers began just a day after the US House Secretary had been quoted saying the coronavirus could cripple global economy up to a year and German Chancellor Angela Merkel said that the pathogen could affect nearly 20% to 30% of global population, ringing some unusual bells that should not be argued at these times of global health emergencies.